Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Cells|November 27, 2021
Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in AdultsJennifer M-L Tjon, Saskia M C Langemeijer, Constantijn J M Halkes
British Journal of Clinical Pharmacology|June 14, 2026
Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiencyMendy Ter Avest, Simon E Koele, Nicole C A J van de Kar, et al.
British Journal of Clinical Pharmacology|November 17, 2022
Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patient friendlinessMendy Ter Avest, Saskia M C Langemeijer, Nicole M A Blijlevens, et al.
Annals of Hematology|March 7, 2024
Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplanMendy Ter Avest, Saskia M C Langemeijer, Nicole M A Blijlevens, et al.
Clinical Pharmacokinetics|June 25, 2025
Model-Informed Precision Dosing of Eculizumab in Patients with Paroxysmal Nocturnal HemoglobinuriaMendy Ter Avest, Saskia M C Langemeijer, Lambertus P W J van den Heuvel, et al.
British Journal of Clinical Pharmacology|January 29, 2021
The potential of individualized dosing of ravulizumab to improve patient-friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costsMendy Ter Avest, Saskia M C Langemeijer, Saskia E M Schols, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|April 21, 2024
Erythroid Predominance in Bone Marrow Biopsies of Acute Myeloid Leukemia Patients after Decitabine Treatment Correlates with Mutation Profile and Complete RemissionFrancesca Tiso, Konnie M Hebeda, Saskia M C Langemeijer, et al.
Therapeutic Drug Monitoring|January 23, 2026
Tailoring Eculizumab Treatment: Evaluation of Model-Informed Precision Dosing for Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic SyndromeAstrid Heida, Mendy Ter Avest, Ron J Keizer, et al.
European Journal of Haematology|February 22, 2023
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomesCharlotte C M Schaap, Floor C J I Heubel-Moenen, Erfan Nur, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 13, 2023
Proteinuria and Exposure to Eculizumab in Atypical Hemolytic Uremic SyndromeMendy Ter Avest, Hilbert Steenbreker, Romy N Bouwmeester, et al.
Pageof 2